GlaxoSmithKline Pharmaceuticals Limited Q4FY21 consolidated net profit at Rs. 14.33 crore

GLAXOSMITHKLINE PHARMACEUTICALS LTD. has reported financial results for the period ended March 31, 2021.

Financial Results (Q4 FY20-21) - QoQ Comparison

The company has reported total income of Rs.843.35 crores during the period ended March 31, 2021 as compared to Rs.871.22 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.14.33 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.156.51 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.0.85 for the period ended March 31, 2021 as compared to Rs.9.24 for the period ended December 31, 2020.

Financials	Q4 FY20-21	Q3 FY20-21	% Change
Total Income	₹ 843.35 crs	₹ 871.22 crs	-3.2%
Net Profit	₹ 14.33 crs	₹ 156.51 crs	-90.84%
EPS	₹ 0.85	₹ 9.24	-90.8%

Financial Results (Q4 FY20-21) - YoY Comparison

The company has reported total income of Rs.843.35 crores during the period ended March 31, 2021 as compared to Rs.791.62 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.14.33 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.138.07 crores for the period ended March 31, 2020.

The company has reported EPS of Rs.0.85 for the period ended March 31, 2021 as compared to Rs.8.15 for the period ended March 31, 2020.

Financials	Q4 FY20-21	Q4 FY19-20	% Change
Total Income	₹ 843.35 crs	₹ 791.62 crs	6.53%
Net Profit	₹ 14.33 crs	₹ 138.07 crs	-89.62%
EPS	₹ 0.85	₹ 8.15	-89.57%

Financial Results (Year ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.3309.44 crores during the 12 months period ended March 31, 2021 as compared to Rs.3303.39 crores during the 12 months period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.358.15 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.93.20 crores for the 12 months period ended March 31, 2020.

The company has reported EPS of Rs.21.14 for the 12 months period ended March 31, 2021 as compared to Rs.5.50 for the 12 months period ended March 31, 2020.

Financials	Year Ended FY20-21	Year Ended FY19-20	% Change
Total Income	₹ 3309.44 crs	₹ 3303.39 crs	0.18%
Net Profit	₹ 358.15 crs	₹ 93.20 crs	284.28%
EPS	₹ 21.14	₹5.50	284.36%

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, "Our relentless patient focus helped us revitalise growth through the year and emerge with renewed resilience in Q4 as we notched double-digit growth across some of our focus brands. Our established portfolio made gains in their market share in respective categories, particularly in the anti-infectives and pain therapeutic areas which have been crucial in the fight against COVID. We also continued to maintain our leadership in dermatology. This growth has further strengthened our resolve to ensure patients get access to our medicines and vaccines that can make that lifesaving difference.

During the year we saw vaccines gaining more significance than ever, GSK continues to be the No. 1 vaccines company in the self-pay segment, propelled by impressive growth towards the end of the year with almost 40% value market share in represented segments. In September 2020, notwithstanding the lockdown, we launched Fluarix Tetra to combat influenza and continued to build on the momentum of our recently launched brand Menveo which had demonstrated promising success, positioning us to focus on our innovation pipeline and the prospect of introducing new launches.

Another priority for us remains employee safety and wellbeing which are complemented by our role as a responsible corporate citizen. We have mobilised support on the ground, by donating to our established humanitarian response partner, Direct Relief in addition to the employee payroll giving initiative. We were the first multinational pharmaceutical company to return to the field as lockdown restrictions were lifted and we continue to cater to market needs with agility by leveraging the scale afforded to us by our investments in digital tools."

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs.1515.75 as compared to the previous close of Rs. 1518.15. The total number of shares traded during the day was 6456 in over 1077 trades.

The stock hit an intraday high of Rs. 1545 and intraday low of 1505.95. The net turnover during the day was Rs. 9863995.

Source : Equity Bulls

Keywords